Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Research & Development (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Research & Development for 8 consecutive years, with $9.8 million as the latest value for Q1 2025.

  • On a quarterly basis, Research & Development changed N/A to $9.8 million in Q1 2025 year-over-year; TTM through Mar 2025 was $53.1 million, a N/A change, with the full-year FY2025 number at $62.4 million, up 65.62% from a year prior.
  • Research & Development was $9.8 million for Q1 2025 at Akebia Therapeutics, down from $9.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $74.7 million in Q3 2021 to a low of $3.0 million in Q2 2021.
  • A 4-year average of $27.0 million and a median of $26.0 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 94.32% in 2021, then soared 767.57% in 2022.
  • Akebia Therapeutics' Research & Development stood at $29.6 million in 2021, then grew by 10.89% to $32.8 million in 2022, then plummeted by 69.9% to $9.9 million in 2023, then decreased by 1.13% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Research & Development are $9.8 million (Q1 2025), $9.9 million (Q4 2023), and $13.3 million (Q3 2023).